The activated clotting time (ACT) test measures how many seconds it takes whole blood to clot after a clot-starting substance is added. It is used mainly during procedures that require high-dose unfractionated heparin, such as cardiopulmonary bypass, cardiac catheterization, vascular procedures, some dialysis settings, and extracorporeal membrane oxygenation (ECMO). ACT gives a fast bedside result, so clinicians can adjust heparin while a procedure is happening instead of waiting for a central laboratory result.
An ACT result is not a general “blood thickness” score. It reflects clotting under specific test conditions and is strongly affected by the device, activator, temperature, platelet count, fibrinogen level, hemodilution, and the clinical setting. A high ACT often means stronger anticoagulation or slower clot formation; a low ACT during heparin therapy can mean inadequate anticoagulation and a higher risk of clotting in catheters, circuits, or surgical equipment.
- ACT measures clotting time in seconds using whole blood, usually at the bedside or in the operating room.
- ACT is used most often to monitor high-dose unfractionated heparin, not routine warfarin or direct oral anticoagulant therapy.
- A typical ACT without heparin is about 70–120 seconds, but each device and laboratory sets its own reference range.
- During heparin therapy, common targets range from about 180–240 seconds for some procedures to more than 400–480 seconds during cardiopulmonary bypass.
- A high ACT can reflect heparin effect, low clotting factors, low platelets, low fibrinogen, hypothermia, hemodilution, or device-related variation.
- Urgent follow-up matters when an abnormal ACT occurs with active bleeding, a clotting event, a blocked circuit, recent heparin exposure, or concern for heparin resistance.
Table of Contents
- What the ACT Test Measures
- When ACT Testing Is Used
- ACT Normal Range and Heparin Targets
- How the ACT Test Is Done
- What High ACT Results Mean
- What Low ACT Results Mean
- ACT vs aPTT, Anti-Xa, and Other Clotting Tests
- Factors That Affect ACT Accuracy
- Questions to Ask About ACT Results
What the ACT Test Measures
The ACT test measures the time it takes a fresh whole-blood sample to form a clot after it is exposed to an activator. The result is reported in seconds. A longer ACT means the blood took longer to clot under the test conditions. A shorter ACT means the blood clotted faster.
Unlike many coagulation tests, ACT uses whole blood rather than plasma. Whole blood contains red blood cells, white blood cells, platelets, clotting proteins, and other blood components. This makes ACT useful during procedures where the patient’s blood is exposed to artificial surfaces, tubing, catheters, oxygenators, dialysis circuits, or a heart-lung machine.
ACT mainly reflects the effect of unfractionated heparin at doses high enough to make other clotting tests less practical. Heparin works by strengthening antithrombin, a natural anticoagulant protein that slows major clotting enzymes, especially thrombin and factor Xa. When heparin effect is strong, the ACT usually rises because clot formation takes longer.
ACT is not a precise measurement of the heparin concentration in blood. It is a functional clotting test. That means it shows how the sample behaves, not exactly how much heparin is present. Two patients with the same heparin dose can have different ACT results because of differences in antithrombin level, platelet count, fibrinogen, inflammation, body temperature, blood dilution, and the ACT device used.
ACT is also different from a general bleeding-risk test. A prolonged ACT may suggest increased bleeding risk in the right setting, especially during heparin treatment, but it does not predict bleeding by itself. Clinicians interpret ACT alongside the procedure, heparin dose, timing, surgical field, blood loss, platelet count, fibrinogen, hemoglobin, and other coagulation tests.
The test is most useful because it is fast. In an operating room or catheterization lab, a clinician may need to know within minutes whether the blood is anticoagulated enough to prevent clotting in a circuit or catheter. ACT provides that quick procedural answer.
When ACT Testing Is Used
ACT testing is used when clinicians need rapid heparin monitoring during procedures that carry a high clotting risk. It is not usually ordered during a routine checkup.
Common ACT uses include:
- Cardiopulmonary bypass during open-heart surgery
- Coronary angioplasty and stent procedures
- Cardiac catheterization procedures that use unfractionated heparin
- Vascular surgery and endovascular procedures
- ECMO support in some centers
- Hemodialysis or other extracorporeal blood circuits in selected cases
- Assessment of heparin reversal after protamine in the operating room
During cardiopulmonary bypass, blood passes through a heart-lung machine. Contact with artificial surfaces activates platelets and clotting proteins. Without strong anticoagulation, clots can form in the circuit, oxygenator, or patient’s blood vessels. ACT helps the team confirm that heparin has produced enough anticoagulation before bypass starts and that anticoagulation remains adequate during the case.
During coronary or vascular procedures, ACT helps clinicians balance two risks: clotting around catheters and wires versus bleeding from access sites or surgical areas. A low ACT during the procedure may lead to more heparin. A very high ACT, especially with bleeding, may lead to holding heparin, giving protamine, or checking other causes of impaired clotting.
In ECMO, ACT is still used in some hospitals because it is fast and available at the bedside. However, ECMO patients often have inflammation, platelet activation, low fibrinogen, low antithrombin, hemodilution, bleeding, thrombosis, and changing heparin response. For that reason, many teams use ACT together with anti-Xa testing for heparin monitoring, aPTT, fibrinogen, platelet count, antithrombin activity, or viscoelastic testing such as TEG or ROTEM.
ACT is not the usual test for monitoring long-term anticoagulants. Warfarin is monitored with PT/INR, not ACT. Standard lower-dose unfractionated heparin infusions outside procedural settings are often monitored with aPTT or anti-Xa instead. Low-molecular-weight heparins, such as enoxaparin, are usually not monitored with ACT.
ACT Normal Range and Heparin Targets
A typical ACT in a person not receiving heparin is about 70–120 seconds. Some methods use wider reference intervals, and some devices report normal values up to about 180 seconds. The correct reference range is always the range provided by the facility and device that performed the test.
ACT targets during heparin therapy vary widely because the desired anticoagulant effect depends on the procedure. A target that is appropriate for a catheter procedure may be unsafe for cardiopulmonary bypass, and a bypass target may be far higher than needed for dialysis or lower-intensity extracorporeal support.
| Setting | Common ACT value or target | How to interpret it |
|---|---|---|
| No heparin | About 70–120 seconds | Often considered a typical baseline range, depending on the device |
| Moderate procedural heparin effect | About 180–240 seconds | Used in some settings where heparin is needed but bypass-level anticoagulation is not required |
| Cardiac catheterization or vascular procedures | Often about 250–300 seconds or higher, depending on the procedure and device | Target depends on local protocol, access site, anticoagulant strategy, and bleeding risk |
| Cardiopulmonary bypass | Often more than 400–480 seconds | High-dose heparin is needed to prevent clotting in the bypass circuit |
| ECMO | Often lower than bypass targets; protocols vary | ACT alone is often not enough because ECMO patients have many non-heparin factors affecting clotting |
These numbers are practical examples, not universal rules. ACT results are device-specific. A kaolin ACT and a celite ACT may not match. A target validated for one analyzer should not be copied automatically to another analyzer. Even within the same hospital, the cardiac surgery team, catheterization lab, dialysis unit, and ICU may use different protocols.
The baseline ACT also matters. If a patient’s ACT is prolonged before heparin is given, the team must consider reasons other than heparin, such as clotting factor deficiency, low fibrinogen, severe liver disease, direct thrombin inhibitor exposure, or a sample problem. In that situation, clinicians may use additional tests from a broader coagulation panel rather than relying on ACT alone.
How the ACT Test Is Done
ACT testing usually uses a small sample of fresh whole blood collected from a vein, arterial line, central line, or procedural access line. The sample is placed into a cartridge or tube that contains a clot activator. The analyzer warms and measures the sample, then reports the time to clot formation in seconds.
The process is usually quick. In procedural settings, the result is often available within minutes. This speed is the main reason ACT remains useful during surgery and interventional procedures.
Before the test
No special preparation is usually needed because ACT is commonly performed during a procedure or hospital treatment. The care team already knows the patient’s medication plan, heparin dose, procedure type, and timing.
Before a planned procedure, patients should tell the team about:
- Heparin, enoxaparin, warfarin, apixaban, rivaroxaban, dabigatran, or other anticoagulants
- Aspirin, clopidogrel, ticagrelor, prasugrel, or other antiplatelet medicines
- Prior heparin-induced thrombocytopenia
- Liver disease, kidney disease, inherited bleeding disorders, or prior severe bleeding
- Recent transfusion, major surgery, pregnancy, infection, or critical illness
Patients should not stop prescribed anticoagulants or antiplatelet drugs unless the treating clinician gives clear instructions. Stopping these medicines without guidance can raise the risk of heart attack, stroke, stent thrombosis, pulmonary embolism, or another serious clotting event.
During heparin monitoring
ACT may be checked before heparin is given to establish a baseline. After heparin administration, the test is repeated to confirm that the ACT has reached the procedural target. During longer procedures, ACT is repeated at set intervals, often every 20–30 minutes during cardiopulmonary bypass or according to local protocol.
If the ACT is below target, the clinician may give more heparin. If the ACT is far above target or bleeding occurs, the clinician may adjust anticoagulation, review other labs, or use protamine to reverse heparin after the procedure. Protamine binds heparin and reduces its anticoagulant effect, but it must be dosed carefully because too much protamine can also interfere with clotting.
After the procedure
ACT may be repeated after protamine reversal or before removing certain catheters. A falling ACT suggests that heparin effect is wearing off or has been reversed. The team still checks the patient clinically because bleeding can occur even when ACT appears acceptable, especially if platelets, fibrinogen, surgical hemostasis, or blood pressure are contributing factors.
What High ACT Results Mean
A high ACT means the blood sample took longer than expected to clot. During heparin therapy, this often means a stronger heparin effect. Outside heparin therapy, or when the ACT is higher than expected for the dose, other causes must be considered.
Common causes of high ACT include:
- High-dose unfractionated heparin
- Residual heparin after a procedure
- Incomplete heparin reversal after protamine
- Low fibrinogen
- Low platelet count or impaired platelet function
- Hemodilution from IV fluids or bypass prime solution
- Hypothermia during surgery
- Severe liver dysfunction with reduced clotting factor production
- Clotting factor deficiencies
- Direct thrombin inhibitors, such as bivalirudin or argatroban
- Sample contamination from a heparinized line
- Device, cartridge, or operator-related variation
A high ACT is expected during cardiopulmonary bypass. In that setting, a high result is not automatically a problem; it is often the intended effect. The concern arises when the ACT is above the target for the procedure, remains prolonged after reversal, or occurs with active bleeding.
A high ACT with bleeding requires fast clinical evaluation. The team may look at the surgical field, blood pressure, temperature, platelet count, fibrinogen, hemoglobin, aPTT, PT/INR, ionized calcium, and viscoelastic testing if available. Fibrinogen is especially important because low fibrinogen weakens clot formation even if heparin reversal is adequate. Platelet count and function also matter because ACT uses whole blood and can be prolonged when platelet-related clot formation is impaired.
High ACT does not always mean “too much heparin.” For example, a patient on bypass may have a long ACT partly because of hypothermia and hemodilution. A patient with liver failure may have prolonged clotting from reduced clotting factors. A patient with a heparin-contaminated sample may have a falsely high ACT that does not match the patient’s actual circulation. When results do not fit the clinical picture, repeat testing from a clean sample often helps.
A persistently high ACT after heparin reversal may prompt clinicians to consider residual heparin, excess protamine, low fibrinogen, platelet dysfunction, factor deficiency, or ongoing dilution. Management depends on the cause, not the ACT number alone.
What Low ACT Results Mean
A low ACT means the sample clotted faster than expected. In a person not receiving heparin, a low or short ACT usually has limited meaning. ACT is not commonly used to diagnose excess clotting tendency in everyday outpatient care.
During heparin-treated procedures, a low ACT matters because it can mean anticoagulation is not strong enough. If blood is passing through catheters, stents, bypass circuits, dialysis tubing, ECMO tubing, or an oxygenator, inadequate anticoagulation can allow clot formation. Clots in these settings can block equipment, reduce oxygenator function, cause emboli, or contribute to stroke, heart attack, limb ischemia, or circuit failure.
Common causes of low or below-target ACT during heparin therapy include:
- Not enough heparin for the procedure
- Delayed or missed heparin dose
- Heparin resistance
- Low antithrombin activity
- High factor VIII or fibrinogen from inflammation or acute illness
- Increased heparin-binding proteins
- High platelet factor 4 release from platelet activation
- Technical or sampling issues
- A target range that does not match the ACT device being used
Heparin resistance means the ACT does not rise as expected after an appropriate heparin dose. It is especially important in cardiac surgery because bypass should not begin until anticoagulation is adequate. Heparin resistance can occur when antithrombin is low, because heparin needs antithrombin to work. It can also occur during inflammation, prolonged preoperative heparin exposure, critical illness, pregnancy, thrombocytosis, or after major clotting activation.
When heparin resistance is suspected, the team may give additional heparin, check antithrombin activity, use a heparin concentration assay, check anti-Xa, give antithrombin concentrate, use plasma in selected cases, or switch to another anticoagulant if heparin is unsafe or ineffective. The exact response depends on the urgency of the procedure and the patient’s bleeding and clotting risks.
A low ACT after protamine reversal is usually expected because the purpose of protamine is to reduce heparin effect. Even then, clinicians continue to watch for bleeding, thrombosis, and rebound heparin effect. Rebound can occur when heparin redistributes from tissues back into the bloodstream after the initial reversal.
ACT vs aPTT, Anti-Xa, and Other Clotting Tests
ACT is one of several tests used to evaluate clotting and anticoagulation. It is fast and practical, but it is not the most specific heparin test.
| Test | Sample type | Main use | Main limitation |
|---|---|---|---|
| ACT | Whole blood | Rapid high-dose heparin monitoring during procedures | Affected by platelets, temperature, dilution, fibrinogen, device type, and non-heparin factors |
| aPTT | Plasma | Moderate-dose unfractionated heparin monitoring and evaluation of prolonged intrinsic-pathway clotting | Less useful at very high heparin levels; affected by factor deficiencies, lupus anticoagulant, inflammation, and reagents |
| Anti-Xa | Plasma | More specific assessment of heparin activity against factor Xa | May be affected by assay design, antithrombin dependence, high bilirubin, hemolysis, lipemia, and timing |
| PT/INR | Plasma | Warfarin monitoring and evaluation of extrinsic/common pathway clotting | Not useful for ACT-guided high-dose procedural heparin monitoring |
| Fibrinogen | Plasma | Assessment of clot-building protein needed for stable fibrin clot formation | Does not measure heparin effect directly |
| TEG or ROTEM | Whole blood | Global clot formation, clot strength, and fibrinolysis assessment | Requires specific equipment, expertise, and protocol-based interpretation |
The aPTT test is commonly used for unfractionated heparin infusions outside high-dose procedural settings. It measures clotting through the intrinsic and common pathways in plasma. However, aPTT becomes less practical at the high heparin levels used during cardiopulmonary bypass because clotting times may be too prolonged or less responsive in the needed range.
Anti-Xa testing estimates heparin activity more directly than ACT or aPTT, because it measures inhibition of factor Xa. Many hospitals use anti-Xa for unfractionated heparin infusions, especially when aPTT is unreliable. During ECMO, anti-Xa is often used along with other tests because no single test fully captures bleeding and clotting risk.
PT/INR is different. INR is used mainly for warfarin monitoring and for evaluating parts of the coagulation system affected by vitamin K deficiency, liver dysfunction, or certain factor deficiencies. It is not the right test for high-dose procedural heparin monitoring. When PT/INR is abnormal at the same time as ACT, clinicians look for broader clotting problems, including liver disease, vitamin K deficiency, dilutional coagulopathy, or disseminated intravascular coagulation.
Platelet testing may also matter. ACT uses whole blood, and platelet number or function can influence clot formation. A low platelet count can contribute to bleeding even when heparin has been reversed. A very high platelet count or platelet activation may also change heparin response. If platelet number is part of the concern, clinicians interpret ACT with the platelet count blood test and other markers.
Factors That Affect ACT Accuracy
ACT results vary more than many routine laboratory tests. The result depends not only on the patient’s clotting system but also on the instrument, cartridge, activator, temperature, sample source, and timing.
Important factors that affect ACT include:
- Device type: Different ACT analyzers can give different values from the same blood sample.
- Activator: Kaolin, celite, glass beads, and other activators do not behave identically.
- Temperature: Hypothermia prolongs clotting and can raise ACT during cardiac surgery.
- Hemodilution: Large fluid volumes or bypass prime solution dilute clotting factors and platelets.
- Platelets: Low platelet count or platelet dysfunction can prolong ACT.
- Fibrinogen: Low fibrinogen weakens clot formation and can prolong clotting measures.
- Antithrombin: Low antithrombin can reduce heparin response and contribute to heparin resistance.
- Inflammation: High factor VIII and fibrinogen can shorten clotting times or reduce apparent heparin response.
- Sampling site: Blood drawn from a heparinized line can falsely prolong ACT.
- Timing: ACT changes after heparin dosing, during bypass, after protamine, and as body temperature changes.
Because of these variables, ACT is best used as a protocol-based procedural tool, not an isolated lab value. Hospitals validate their own ACT targets for specific devices and procedures. This is why a result of 300 seconds may be adequate in one procedural setting but too low for cardiopulmonary bypass.
Trend matters. A single ACT value gives one snapshot. A pattern of results shows whether anticoagulation is rising after heparin, staying stable during the procedure, falling after protamine, or behaving unexpectedly. Sudden changes should prompt a check of timing, sample quality, device function, heparin dose, and the patient’s clinical status.
ACT is also less reliable in complex critical illness. In ECMO, for example, bleeding and thrombosis often reflect several overlapping problems: platelet activation, acquired von Willebrand changes, fibrinogen shifts, inflammation, circuit factors, transfusion, liver dysfunction, kidney dysfunction, antithrombin changes, and anticoagulant exposure. ACT may remain useful as a quick bedside test, but it rarely provides the whole anticoagulation picture.
Questions to Ask About ACT Results
Most ACT testing happens in a hospital or procedural setting, so patients often see the result only in the medical record. A single abnormal ACT without context can look alarming. The useful question is not only whether the value was high or low, but whether it was appropriate for that moment in care.
Helpful questions include:
- What ACT target was being used for my procedure?
- Was my ACT measured before heparin, after heparin, during the procedure, or after protamine?
- Was the result expected for the heparin dose I received?
- Did I need extra heparin, protamine, antithrombin, plasma, platelets, cryoprecipitate, or other blood products?
- Was there concern for heparin resistance?
- Were my platelet count, fibrinogen, aPTT, anti-Xa, PT/INR, or TEG/ROTEM results also abnormal?
- Did the ACT result change my bleeding or clotting risk after the procedure?
- Should any anticoagulant or antiplatelet medication be changed after discharge?
Patients should seek urgent medical attention after a recent procedure or heparin exposure if they develop heavy bleeding, black or bloody stools, vomiting blood, severe headache, sudden weakness, chest pain, shortness of breath, painful leg swelling, fainting, confusion, or rapidly expanding bruising near a catheter or surgical site.
ACT results should always be interpreted by the treating team because the meaning depends on timing and context. A high ACT during bypass may be the desired result. The same value after reversal with active bleeding may require immediate evaluation. A low ACT before heparin may mean little. A low ACT after heparin in a bypass case may signal inadequate anticoagulation and a serious procedural risk.
References
- 2024 EACTS/EACTAIC/EBCP Guidelines on cardiopulmonary bypass in adult cardiac surgery 2025 (Guideline)
- POCT14 | Point-of-Care Coagulation Testing and Anticoagulation Monitoring 2020 (Guideline)
- Activated Clotting Time and Haemostatic Complications in Patients Receiving ECMO Support: A Systematic Review 2025 (Systematic Review)
- Heparin resistance management during cardiac surgery: a literature review and future directions 2024 (Review)
- Anticoagulation Monitoring Using Activated Clotting Time in Patients Receiving Extracorporeal Membrane Oxygenation: A Meta-Analysis of Correlation Coefficients 2024 (Systematic Review)
- Activated Coagulation Time 2024 (Patient Education)
Disclaimer
This article is for educational purposes only and does not replace care from a qualified clinician. ACT targets and heparin decisions vary by procedure, device, hospital protocol, and patient condition. Anyone with bleeding, symptoms of a clot, or questions after heparin treatment should contact their healthcare team promptly.
